BLCO250117C5000
- 0.00
- 0.000.00%
Bausch + Lomb Corp. Newsroom
Express News | Live On CNBC, Bausch + Lomb CEO Discusses Sale Rumors, Shares See Volume To The Upsde
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press Release: Bausch + Lomb Bolsters Pipeline With Acquisition of Whitecap Biosciences
Bausch + Lomb Launches EnVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating
InflammX Therapeutics Entered Option Agreement With Bausch + Lomb Granting Right To Be Acquired By BLCO
Character Biosciences Announces Collaboration With Bausch + Lomb to Transform Ophthalmology With Precision Medicine
City Therapeutics Announces Strategic Collaboration With Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising Challenge
Evercore Upgrades Bausch + Lomb Corp.(BLCO.US) to Buy Rating, Raises Target Price to $22
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating
Bausch + Lomb Insider Ups Holding During Year
Jefferies Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $25
Bausch + Lomb Stock Extends Gains as Jefferies Describes It as an 'Undervalued Asset'
Express News | B of A Securities Reinstates Underperform on Bausch & Lomb, Announces $18 Price Target
BofA Securities Downgrades Bausch + Lomb Corp.(BLCO.US) to Sell Rating, Announces Target Price $18
Bausch & Lomb Edges Higher After Confirming Sales Process